A real-world study from India demonstrated that ultralow-dose nivolumab (40 mg every 2 weeks) combined with chemotherapy ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung ...

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...

MONDAY, April 21, 2025 (HealthDay News) — Immunotherapy might help keep lung cancer at bay for months or even years after the ...

Led by Friends, collaborators included Biodesix alongside organizations from industry, government, academia, and advocacy ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...

Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) ...

Patients who discontinued cancer immunotherapy because of immune-related adverse events (irAEs) often had durable benefits ...

The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.

A breakthrough in cancer treatment may soon change how some of the most aggressive tumors are managed. A small, ...